Tirzepatide is noninferior to dulaglutide with respect to a composite of death from cardiovascular (CV) causes, myocardial ...

Another glucagon-like peptide-1 (GLP1) agonist, dulaglutide (Trulicity, Lilly), is poised to be a new option for glycemic control in youth ages 10 to 18 with type 2 diabetes, given as a weekly ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio NEW ORLEANS — Young people with type 2 ...

- Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the only non-insulin, injectable diabetes treatment available in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 25, 2014 ...

Results from a phase 3 study of patients with type 2 diabetes uncontrolled with metformin indicate that adding injections of the investigational glucagonlike peptide 1 (GLP-1)–receptor agonist ...

Patients on tirzepatide also experienced more metabolic benefits, such as greater reductions in weight and HbA1c, compared ...

Dulaglutide reduces liver fat content in patients with type 2 diabetes (T2D) and nonalcoholic fatty liver disease, when used in combination with standard T2D treatment. Although previous data show ...

Adults with type 2 diabetes and mild to moderate chronic kidney disease assigned the once-weekly GLP-1 receptor agonist dulaglutide experienced a similar reduction in HbA1c vs. those assigned insulin ...

Trulicity is a prescription drug prescribed to lower blood glucose levels and treat type diabetes. Although it is FDA approved for treating diabetes it is not approved for weight loss. Despite this ...

diabetes test strip Findings from a phase 3 study showed that dulaglutide (Trulicity; Lilly) at higher investigational doses demonstrated superiority in significantly reducing hemoglobin A1c in ...